<DOC>
	<DOCNO>NCT00001526</DOCNO>
	<brief_summary>Uveitis refers intraocular inflammatory disease important cause visual loss . Standard systemic immunosuppressive medication uveitis cause significant adverse effect . Consequently , effective treatment safer side effect profile highly desirable . This pilot study permit enrollment 12 adult non-infectious intermediate posterior uveitis require treatment maintain visual function . This extend protocol begin evaluation safety potential efficacy intravenous ( IV ) daclizumab treatment uveitis reduce eliminate standard medication commensurate standard care . As subcutaneous ( SC ) daclizumab treatment become available , eligible participant offer continue daclizumab treatment use new SC formulation , though may elect remain IV treatment . If therapeutic benefit sustain use SC formulation , maintenance therapy continue clinically indicate . Participants repeatedly fail SC therapy permit revert IV daclizumab regimen previously use , may exit study treatment failure . SC treatment begin short SC induction 2 mg/kg follow 1 mg/kg treatment 4-week schedule protocol originally specify . Participants monitor routinely dose receive additionally participate pharmacokinetic study monitor SC formulation bioavailability . Daclizumab humanize anti-Tac monoclonal antibody ( HAT , Zenapax ) interfere inflammatory process involvement interleukin 2 receptor ( IL-2R ) . During first 5 year study , IV product available . The SC formulation available contain daclizumab drug product . Preliminary study indicate SC formulation well tolerate normal control subject autoimmune disease patient repeat dos 2 mg/kg . The primary objective examine safety potential efficacy IV later , SC daclizumab , continue reduce immunosuppressive medication commensurate standard care . Primary safety outcomes discontinuation study therapy due reduce vision occurrence adverse event . Secondary outcome measure include visual acuity grade immunosuppressive medication , anterior chamber vitreous cell , vitreous haze .</brief_summary>
	<brief_title>ANTI-TAC THERAPY FOR UVEITIS</brief_title>
	<detailed_description>Uveitis refers intraocular inflammatory disease important cause visual loss . Standard systemic immunosuppressive medication uveitis cause significant adverse effect . Consequently , effective treatment safer side effect profile highly desirable . This pilot study permit enrollment 12 adult non-infectious intermediate posterior uveitis require treatment maintain visual function . This extend protocol begin evaluation safety potential efficacy intravenous ( IV ) daclizumab treatment uveitis reduce eliminate standard medication commensurate standard care . As subcutaneous ( SC ) daclizumab treatment become available , eligible participant offer continue daclizumab treatment use new SC formulation , though may elect remain IV treatment . If therapeutic benefit sustain use SC formulation , maintenance therapy continue clinically indicate . Participants repeatedly fail SC therapy permit revert IV daclizumab regimen previously use , may exit study treatment failure . SC treatment begin short SC induction 2 mg/kg follow 1 mg/kg treatment 4-week schedule protocol originally specify . Participants monitor routinely dose receive additionally participate pharmacokinetic study monitor SC formulation bioavailability . Daclizumab humanize anti-Tac monoclonal antibody ( HAT , Zenapax ) interfere inflammatory process involvement interleukin 2 receptor ( IL-2R ) . During first 5 year study , IV product available . The SC formulation available contain daclizumab drug product . Preliminary study indicate SC formulation well tolerate normal control subject autoimmune disease patient repeat dos 2 mg/kg . The primary objective examine safety potential efficacy IV later , SC daclizumab , continue reduce immunosuppressive medication commensurate standard care . Primary safety outcomes discontinuation study therapy due reduce vision occurrence adverse event . Secondary outcome measure include visual acuity grade immunosuppressive medication , anterior chamber vitreous cell , vitreous haze .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>INCLUSION CRITERIA Participant 18 year age old . Participant diagnosis sightthreatening , intermediate posterior uveitis least three month duration prior orginal enrollment , require treatment control intraocular inflammatory disease least 20 mg/day prednisone ( equivalent ) combination two antiinflammatory treatment uveitis , include example prednisone , cyclophosphamide , cyclosporine , azathioprine , mycophenolate mofetil , methotrexate , etc . Participant exhibit intolerance indicate systemic medication require uveitis , though uveitis may control , wish take present medication due potential actual unacceptable side effect . Participant visual acuity least one eye 20/63 better ( ETDRS , logMAR less 0.54 ) . Participant normal renal liver function evidence bad mild abnormality define WHO/NEI criterion . Participant currently pregnant lactate . Participant reproductive potential sexually active agrees use acceptable birth control method throughout course study . EXCLUSION CRITERIA Participants age 18 year . Participants receive previous treatment IL2 direct monoclonal antibody investigational agent would interfere ability evaluate safety , efficacy pharmacokinetics daclizumab . Participants history diagnosis Behcet 's disease . Participant significant active infection . Participant history cancer ( nonmelanoma skin cancer ) diagnose within past 5 year . Participant hypersensitive fluorescein dye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 6, 2007</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Interleukin 2 Receptor</keyword>
	<keyword>Daclizumab</keyword>
	<keyword>HAT</keyword>
	<keyword>Zenapax</keyword>
	<keyword>Interleukin 2</keyword>
</DOC>